LABT (Lakewood-Amedex Biotherapeutics) Price-to-Tangible-Book: (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $2.37
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Price-to-Tangible-Book?

As of today (2026-08-13), Lakewood-Amedex Biotherapeutics's share price is $2.37. Lakewood-Amedex Biotherapeutics's Tangible Book per Share of Mar. 2026 for the quarter that ended in Mar. 2026 was $-2.03. Hence, Lakewood-Amedex Biotherapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Lakewood-Amedex Biotherapeutics's Price-to-Tangible-Book or its related term are showing as below:

LABT's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 3.26
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Lakewood-Amedex Biotherapeutics's share price is $2.37. Lakewood-Amedex Biotherapeutics's Book Value per Sharefor the quarter that ended in Mar. 2026 was $-2.03. Hence, Lakewood-Amedex Biotherapeutics's P/B Ratio of today is .

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Lakewood-Amedex Biotherapeutics Price-to-Tangible-Book Related Terms

Lakewood-Amedex Biotherapeutics Price-to-Tangible-Book Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Price-to-Tangible-Book Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
Price-to-Tangible-Book
0.00 0.00 0.00

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Price-to-Tangible-Book Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

LABT vs CDIO, JAGX, TCRT: Price-to-Tangible-Book Comparison

For the Biotechnology subindustry, Lakewood-Amedex Biotherapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lakewood-Amedex Biotherapeutics Price-to-Tangible-Book vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lakewood-Amedex Biotherapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Lakewood-Amedex Biotherapeutics's Price-to-Tangible-Book falls into.


LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Price-to-Tangible-Book is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Price-to-Tangible-Book Calculation

Lakewood-Amedex Biotherapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2026 )
=2.37/-2.029
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price to Tangible Book=Market Cap/Tangible Equity
=Market Cap/(Total Stockholders Equity-Preferred Stock-Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.37
Price